Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immutep Limited - American Depositary Shares
(NQ:
IMMP
)
2.030
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immutep Limited - American Depositary Shares
< Previous
1
2
3
Next >
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
November 14, 2024
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy.
Via
Benzinga
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
November 14, 2024
From
Immutep Limited
Via
GlobeNewswire
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September
September 16, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
July 29, 2024
Via
Benzinga
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 12, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
July 12, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via
InvestorPlace
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
July 12, 2024
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer...
Via
Benzinga
Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
July 12, 2024
Via
Benzinga
Immutep Touts Encouraging Data From Efti Triple Combination Therapy In Lung Cancer Setting
May 24, 2023
Via
Benzinga
Maxim Group Maintains Buy Rating for Immutep: Here's What You Need To Know
May 18, 2023
Via
Benzinga
Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 27, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
June 27, 2024
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 24, 2024
Via
Benzinga
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
April 24, 2024
Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 24, 2024
Via
Benzinga
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
April 24, 2024
From
Immutep Limited
Via
GlobeNewswire
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
March 05, 2024
Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic breast cancer. No serious adverse events were reported, and a 50% overall...
Via
Benzinga
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
October 24, 2023
From
Immutep Limited
Via
GlobeNewswire
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
October 23, 2023
From
Immutep Limited
Via
GlobeNewswire
7 Stocks That Could Triple Your Money by 2024
August 09, 2023
If you want to get well ahead of the market and don’t mind the risk factor, check out these stocks to triple your money.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
August 03, 2023
Via
Benzinga
3 Best Penny Stocks Under $3 to Buy in June
June 14, 2023
If you don’t mind the immense risks associated with high-potential opportunities, these best penny stocks under $3 could be for you.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 24, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 17, 2023
Via
Benzinga
Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial
May 17, 2023
Immutep Limited's (NASDAQ: IMMP) lead candidate — a soluble LAG-3 protein, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) —
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 17, 2023
Via
Benzinga
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
May 17, 2023
From
Immutep Limited
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May 17, 2023
We're starting off Wednesday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning!
Via
InvestorPlace
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
May 01, 2023
From
Immutep Limited
Via
GlobeNewswire
7 Best Penny Stocks Under $3 to Buy in April
April 12, 2023
If you have the audacity to consider ultra-speculative opportunities, these ideas for best penny stocks under $3 might be appealing.
Via
InvestorPlace
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.